Vanta Bioscience Ltd
Incorporated in 2016, Vanta Bioscience
Ltd is in the business of Preclinical Activities.[1]
- Market Cap ₹ 15.3 Cr.
- Current Price ₹ 24.2
- High / Low ₹ 75.2 / 19.7
- Stock P/E
- Book Value ₹ 29.3
- Dividend Yield 0.00 %
- ROCE 5.34 %
- ROE 0.05 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.83 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -6.66% over past five years.
- Company has a low return on equity of -6.33% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: FMCG Industry: Miscellaneous
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 3.88 | 12.08 | 13.72 | 9.82 | 9.06 | 5.17 | 8.56 | 4.13 | |
| 0.00 | 2.84 | 8.81 | 9.40 | 5.92 | 5.66 | 5.65 | 4.91 | 2.55 | |
| Operating Profit | 0.00 | 1.04 | 3.27 | 4.32 | 3.90 | 3.40 | -0.48 | 3.65 | 1.58 |
| OPM % | 26.80% | 27.07% | 31.49% | 39.71% | 37.53% | -9.28% | 42.64% | 38.26% | |
| 0.00 | 0.05 | 0.23 | 0.11 | 0.02 | 0.17 | 0.63 | 0.05 | 0.05 | |
| Interest | 0.00 | 0.20 | 1.69 | 1.95 | 2.06 | 2.11 | 3.11 | 2.42 | 1.84 |
| Depreciation | 0.00 | 0.57 | 0.71 | 1.19 | 1.25 | 1.32 | 1.25 | 1.24 | 1.22 |
| Profit before tax | 0.00 | 0.32 | 1.10 | 1.29 | 0.61 | 0.14 | -4.21 | 0.04 | -1.43 |
| Tax % | 90.62% | 36.36% | 24.03% | 21.31% | 42.86% | 0.71% | -25.00% | ||
| 0.00 | 0.03 | 0.69 | 0.98 | 0.47 | 0.08 | -4.24 | 0.05 | -1.36 | |
| EPS in Rs | 0.00 | 0.05 | 1.09 | 1.55 | 0.74 | 0.13 | -6.72 | 0.08 | -2.15 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -7% |
| 3 Years: | -4% |
| TTM: | -53% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -55% |
| 3 Years: | -72% |
| TTM: | 48% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -21% |
| 3 Years: | -40% |
| 1 Year: | -62% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -6% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.65 | 5.73 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 |
| Reserves | 2.50 | 10.86 | 15.93 | 17.13 | 17.60 | 17.68 | 13.43 | 13.48 | 12.19 |
| 7.50 | 11.18 | 13.25 | 14.15 | 17.28 | 20.77 | 25.76 | 25.38 | 27.46 | |
| 0.10 | 1.40 | 2.51 | 4.00 | 5.06 | 5.64 | 6.14 | 7.74 | 6.82 | |
| Total Liabilities | 13.75 | 29.17 | 38.00 | 41.59 | 46.25 | 50.40 | 51.64 | 52.91 | 52.78 |
| 12.95 | 17.49 | 17.90 | 20.76 | 29.39 | 36.12 | 37.40 | 37.87 | 37.26 | |
| CWIP | 0.00 | 2.34 | 3.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 4.50 | 3.95 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| 0.80 | 4.84 | 12.45 | 17.83 | 13.86 | 11.28 | 11.24 | 12.04 | 12.52 | |
| Total Assets | 13.75 | 29.17 | 38.00 | 41.59 | 46.25 | 50.40 | 51.64 | 52.91 | 52.78 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|
| -0.26 | -6.75 | -0.06 | 3.17 | 11.01 | 6.70 | 0.64 | 4.55 | |
| -12.95 | -7.53 | -4.70 | -1.56 | -9.96 | -8.08 | -2.53 | -1.67 | |
| 13.66 | 13.93 | 4.96 | -1.80 | -1.07 | 1.38 | 1.88 | -2.81 | |
| Net Cash Flow | 0.44 | -0.36 | 0.20 | -0.20 | -0.02 | 0.00 | 0.00 | 0.07 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 31.04 | 47.14 | 36.18 | 73.59 | 29.01 | 135.55 | 99.78 | |
| Inventory Days | 3,444.69 | 2,409.00 | ||||||
| Days Payable | 228.12 | 119.93 | ||||||
| Cash Conversion Cycle | 3,247.61 | 2,336.21 | 36.18 | 73.59 | 29.01 | 135.55 | 99.78 | |
| Working Capital Days | 237.06 | 260.76 | 322.97 | 338.24 | 244.94 | 404.54 | 211.50 | |
| ROCE % | 2.27% | 8.09% | 8.81% | 6.73% | 5.24% | -2.44% | 5.34% |
Documents
Announcements
- Closure of Trading Window 29 Mar
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 7 Jan
-
Shareholder Meeting / Postal Ballot-Outcome of EGM
4 Jan - Proceedings of the Extra Ordinary General Meeting held.
-
Notice Of EGM To Be Held On 04.01.2025
12 Dec 2024 - Extraordinary General Meeting for loan conversion to equity.
-
EGM On 04.01.2025
7 Dec 2024 - Extra Ordinary General Meeting on January 04, 2025.
Business Overview:[1]
The company is a preclinical contract research organization, offering preclinical safety assessment services for clientele from the Pharmaceutical, Medical Devices, Nutraceuticals, Feed additives, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, the company also provides risk assessment services for evaluating the safety of Active Pharmaceutical Ingredients (API), excipients, extractable and leachable including pharmaceutical impurities resulting due to manufacturing process or degradation
of the product. VBS also provides expert services for the determination of health-based exposure limits e.g. permitted daily exposure or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.
Services Offered:
a) Toxicology[2]
b) Agro-chemical and Chemical Safety[3]
c) Bio Compatibility Studies[4]
d) Diet Formulation[5]
e) Batch Release Test[6]
f) Medical Devices[7]
g) Food Additives[8]
h) Cosmetics[9]